Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution

Michal Kováč(Centre for Human Genetics), Carolina Navas(The Honourable Society of Lincoln's Inn), Stuart Horswell(The Honourable Society of Lincoln's Inn), Max Salm(The Honourable Society of Lincoln's Inn), Chiara Bardella(Centre for Human Genetics), Andrew Rowan(The Honourable Society of Lincoln's Inn), Mark Stares(The Honourable Society of Lincoln's Inn), Francesc Castro-Giner(Centre for Human Genetics), Rosalie Fisher(The Honourable Society of Lincoln's Inn), Elza C. de Bruin(London Cancer), Monika Kováčová(Slovak University of Technology in Bratislava), Maggie Gorman(Centre for Human Genetics), Seiko Makino(Centre for Human Genetics), Jennet Williams(Centre for Human Genetics), Emma Jaeger(Centre for Human Genetics), Angela Jones(Centre for Human Genetics), Kimberley Howarth(Centre for Human Genetics), James Larkin(Royal Marsden NHS Foundation Trust), Lisa Pickering(Royal Marsden NHS Foundation Trust), Martin Gore(Royal Marsden NHS Foundation Trust), David Nicol(Royal Marsden NHS Foundation Trust), Steven Hazell(Royal Marsden NHS Foundation Trust), Gordon Stamp(The Honourable Society of Lincoln's Inn), Tim O’Brien(Guy's and St Thomas' NHS Foundation Trust), Ben Challacombe(Guy's and St Thomas' NHS Foundation Trust), Nik Matthews(The Honourable Society of Lincoln's Inn), Benjamin Phillimore(The Honourable Society of Lincoln's Inn), Sharmin Begum(The Honourable Society of Lincoln's Inn), Adam Rabinowitz(The Honourable Society of Lincoln's Inn), Ignacio Varela(Universidad de Cantabria), Ashish Chandra(Guy's and St Thomas' NHS Foundation Trust), Catherine Horsfield(Guy's and St Thomas' NHS Foundation Trust), Alexander Polson(Guy's and St Thomas' NHS Foundation Trust), Maxine Tran(University of Cambridge), Rupesh I. Bhatt(University of Alabama at Birmingham Hospital), Luigi Terracciano(University Hospital of Basel), Serenella Eppenberger‐Castori(University Hospital of Basel), Andrew Protheroe(Churchill Hospital), Eamonn R. Maher(University of Cambridge), Mona El Bahrawy(Hammersmith Hospital), Stewart Fleming(University of Dundee), Peter J. Ratcliffe(Centre for Human Genetics), Karl Heinimann(University of Basel), Charles Swanton(The Honourable Society of Lincoln's Inn), Ian Tomlinson(Centre for Human Genetics)
Nature Communications
March 19, 2015
Cited by 121Open Access
Full Text

Abstract

Papillary renal cell carcinoma (pRCC) is an important subtype of kidney cancer with a problematic pathological classification and highly variable clinical behaviour. Here we sequence the genomes or exomes of 31 pRCCs, and in four tumours, multi-region sequencing is undertaken. We identify BAP1, SETD2, ARID2 and Nrf2 pathway genes (KEAP1, NHE2L2 and CUL3) as probable drivers, together with at least eight other possible drivers. However, only ~10% of tumours harbour detectable pathogenic changes in any one driver gene, and where present, the mutations are often predicted to be present within cancer sub-clones. We specifically detect parallel evolution of multiple SETD2 mutations within different sub-regions of the same tumour. By contrast, large copy number gains of chromosomes 7, 12, 16 and 17 are usually early, monoclonal changes in pRCC evolution. The predominance of large copy number variants as the major drivers for pRCC highlights an unusual mode of tumorigenesis that may challenge precision medicine approaches.


Related Papers

No related papers found

Powered by citation graph analysis